Skip to main content

Advertisement

Table 5 Summary of the most frequently reported adverse events a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

  GSK933776 dose
Adverse events 1 mg/kg ( N/n = 6/6) 3 mg/kg ( N/n = 6/6) 6 mg/kg ( N/n = 6/6)
Any event 3 (50) 5 (83) 5 (83)
Fatigue 0 2 (33) 2 (33)
Headache 1 (17) 4 (67) 2 (33)
Nausea 0 3 (50) 1 (17)
Vomiting 0 2 (33) 1 (17)
Back pain 1 (17) 2 (33) 1 (17)
Nasopharyngitis 0 0 0
Neck pain 0 1 (17) 1 (17)
Atrial fibrillation 1 (17) 0 1 (17)
Procedural headache 0 1 (17) 1 (17)
  1. aData in parentheses are percentages.